Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sidney Myles

Internal Medicine Hickory, NC Medical Doctor

NPI 1447215900 CMS profile 247186

929 15Th St Ne, Suite 100, Hickory, NC 28601

Open in the dashboard

General payments

$5,060

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sidney Myles of Hickory, NC is reported in the CMS Open Payments database as having received $5,060 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $775 39
2024 General $489 24
2023 General $787 39
2022 General $731 39
2021 General $833 45
2020 General $564 33
2019 General $881 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sidney Myles
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sidney Myles were reported at $775. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sidney Myles Internal Medicine median Middle half National median
2019 $881 $159 $48–$570 $163
2020 $564 $119 $33–$402 $114
2021 $833 $135 $37–$521 $132
2022 $731 $141 $42–$496 $149
2023 $787 $149 $45–$519 $160
2024 $489 $154 $47–$537 $164
2025 $775 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $727 35 payments
  2. Janssen Pharmaceuticals, Inc $404 22 payments
  3. ITI, Inc. $387 19 payments
  4. Alkermes, Inc. $382 21 payments
  5. AbbVie, Inc. $380 22 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $356 23 payments
  7. Lundbeck LLC $326 16 payments
  8. Teva Pharmaceuticals USA, Inc. $295 16 payments
  9. Neurocrine Biosciences, Inc. $294 14 payments
  10. Tris Pharma Inc $191 10 payments
  11. Other $1,319 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,057 268 payments
  2. Education $2 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $578 26 payments
  2. VRAYLAR $366 21 payments
  3. ARISTADA Cns $322 18 payments
  4. ARISTADA Cns $322 18 payments
  5. INVEGA SUSTENNA $308 18 payments
  6. ARISTADA Cns $297 17 payments
  7. ARISTADA Cns $297 17 payments
  8. TRINTELLIX $264 14 payments
  9. CAPLYTA $259 13 payments
  10. REXULTI Psychiatry $236 11 payments
  11. Other $3,816 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

3,752

Median for Psychiatry: 574

Drug cost

$181,534

Median for Psychiatry: $27,624

Branded share of claims

20.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 21 $30,501
Trintellix Vortioxetine Hydrobromide Brand 41 $28,829
Rexulti Brexpiprazole Brand 18 $28,695
Lurasidone Hcl Generic 41 $11,875
Tradjenta Linagliptin Brand 13 $6,783
Quetiapine Fumarate Generic 272 $6,307
Duloxetine Hcl Generic 172 $5,687
Belsomra Suvorexant Brand 11 $4,906
Venlafaxine Hcl Er Venlafaxine Hcl Brand 212 $4,386
Lamotrigine Er Lamotrigine Brand 15 $3,373

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$30,431

Medicare's payments for the services billed

Medicare patients

176

Average age 68

Services billed

500

117 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 44%
Diabetes 30%
Chronic kidney disease 29%
Alzheimer's or dementia 23%
Ischemic heart disease 22%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $43
  • Lundbeck LLC $20
$63 18 —
CAPLYTA
  • ITI, Inc. $60
$60 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $52
$52 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $44
$44 — —
Auvelity
  • Axsome Therapeutics, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record